Tag: lymphNodeStatus

Articles

• African-American breast cancer patients can improve their outcomes
• Tumor characteristics influencing prognosis of triple negative BC

News

12/07/21

Breast cancer characteristics that increase likelihood of late recurrence

05/12/21

Tamoxifen increases long-term survival in women with large tumor size

11/18/17

Late recurrence of ER+ BC linked to primary tumor characteristics

10/18/15

Late recurrence of ER+ breast cancer is more likely for some women

03/22/15

Type 2 diabetes is linked to higher breast cancer stage at diagnosis

07/20/14

HER2 status of lymph nodes can differ from that of primary tumor

11/19/12

Traditional prognostic factors may not predict recurrence after PCR

09/16/12

Axillary node dissection unnecessary for some despite micrometastases

08/12/12

Lymph node negative ER-/PR- BC has less favorable prognosis

06/20/12

Large breast size linked to reduced survival for ER+ breast cancer

12/04/11

Lumpectomy vs. mastectomy rates vary by type of breast cancer

12/02/11

Knowing receptor status of metastases improves treatment decisions

10/21/11

Radiotherapy after lumpectomy reduces long-term recurrence

05/28/11

Triple negative prognosis is influenced by number of positive nodes

10/03/10

Lobular breast cancer micrometastases may be classified incorrectly

09/08/10

Sentinel node micrometastases do not reduce breast cancer survival

03/04/10

Delay in radiotherapy increases risk of local recurrence

Studies

• Is routine axillary staging still required in clinically node negative early breast cancer in women over 74 years? Cite
  Grant K, Po XY, Tiong L. Is routine axillary staging still required in clinically node negative early breast cancer in women over 74 years?. ANZ Journal of Surgery. Wiley; 2024; 10.1111/ans.19313
• ABO Blood Type and Pretreatment Systemic Inflammatory Response Index Associated with Lymph Node Metastasis in Patients with Breast Cancer Cite
  Xiong N, Han W, Yu Z. ABO Blood Type and Pretreatment Systemic Inflammatory Response Index Associated with Lymph Node Metastasis in Patients with Breast Cancer. International Journal of General Medicine. Informa UK Limited; 2024; Volume 17:4823-4833 10.2147/ijgm.s486873
• Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy? Cite
  Record SM, Thomas SM, Dalton J, van den Bruele AB, Chiba A, DiLalla G, et al. Triple-Negative Breast Cancer in Older Patients: Does SLNB Guide Therapy?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-16106-x
• Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution Cite
  An SJ, Thai CHNC, Ismail S, Agala CB, Hoang V, Feeney T, et al. Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-16059-1
• Racial disparities in disease‐specific mortality and surgical management of patients with ductal carcinoma in situ with microinvasion Cite
  Chen JC, Handley D, Elsaid MI, Fisher JL, Owusu‐Brackett N, Azap L, et al. Racial disparities in disease‐specific mortality and surgical management of patients with ductal carcinoma in situ with microinvasion. Journal of Surgical Oncology. Wiley; 2024; 129:1179-1186 10.1002/jso.27625
• Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients Cite
  Richman J, Schuster G, Buus R, Lopez-Knowles E, Dowsett M. Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07311-z
• Abstract PS03-01: Single cell analysis of paired lymph nodes and primary tumors in breast cancer patients Cite
  Fjørtoft M, Rye I, Huse K, Myklebust J, Russnes H, Riis M, et al. Abstract PS03-01: Single cell analysis of paired lymph nodes and primary tumors in breast cancer patients. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PS03-01-PS03-01 10.1158/1538-7445.sabcs23-ps03-01
• Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period Cite
  Quirke N, Cullinane C, Turk M, Shafique N, Evoy D, Geraghty J, et al. Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period. The Breast. Elsevier BV; 2024;:103739 10.1016/j.breast.2024.103739
• Accuracy of sentinel lymph node biopsy in male breast cancer: Systematic review and meta-analysis Cite
  Parpex G, Ottaviani M, Lorphelin H, Mezzadri M, Marchand E, Cahen-Doidy L, et al. Accuracy of sentinel lymph node biopsy in male breast cancer: Systematic review and meta-analysis. The Breast. Elsevier BV; 2024;:103703 10.1016/j.breast.2024.103703
• Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials Cite
  Dayan D, Lukac S, Rack B, Ebner F, Fink V, Leinert E, et al. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01750-0
• Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer Cite
  Göker M, Denys H, Hendrix A, De Wever O, Van de Vijver K, Braems G. Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01745-x
• Prognostic value of axillary lymph node metastases in invasive lobular breast carcinoma Cite
  DEBERTI M, GOUPILLE C, ARBION F, VILDE A, BODY G, OULDAMER L. Prognostic value of axillary lymph node metastases in invasive lobular breast carcinoma. Journal of Gynecology Obstetrics and Human Reproduction. Elsevier BV; 2023;:102665 10.1016/j.jogoh.2023.102665
• Survival After Contralateral Secondary Breast Cancer by Age Group in California Cite
  Perry LM, Keegan THM, Li Q, Bold RJ, Antonino NF, Maguire FB, et al. Survival After Contralateral Secondary Breast Cancer by Age Group in California. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13902-9
• Predictive biological factors for late survival in patients with HER2-positive breast cancer Cite
  Kang Y, Oh SJ, Bae SY, Kim E, Lee Y, Park EH, et al. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2023; 13 10.1038/s41598-023-38200-y
• Hepatitis C virus may accelerate breast cancer progression by increasing mutant p53 and c-Myc oncoproteins circulating levels Cite
  Fathy A, Abdelrazek MA, Attallah AM, Abouzid A, El-Far M. Hepatitis C virus may accelerate breast cancer progression by increasing mutant p53 and c-Myc oncoproteins circulating levels. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3047606/v1
• Prognostic factors in Luminal B-like HER2-negative breast cancer tumors Cite
  Castellarnau-Visús M, Soveral I, Regueiro Espín P, Pineros Manzano J, Del Río M. Prognostic factors in Luminal B-like HER2-negative breast cancer tumors. Surgical Oncology. Elsevier BV; 2023;:101968 10.1016/j.suronc.2023.101968
• Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study Cite
  Taylor C, McGale P, Probert J, Broggio J, Charman J, Darby SC, et al. Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study. BMJ. BMJ; 2023;:e074684 10.1136/bmj-2022-074684
• Axillary Lymph Node Dissection is Associated with Improved Survival Among Men with Invasive Breast Cancer and Sentinel Node Metastasis Cite
  Chung SH, de Geus SWL, Shewmaker G, Romatoski KS, Drake FT, Ko NY, et al. Axillary Lymph Node Dissection is Associated with Improved Survival Among Men with Invasive Breast Cancer and Sentinel Node Metastasis. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13475-7
• Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy Cite
  Sopik V, Lim D, Sun P, Narod SA. Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy. Current Oncology. MDPI AG; 2023; 30:3829-3844 10.3390/curroncol30040290
• Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer Cite
  Kuhar CG, Borštnar S, Gazić B, Matos E. Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer. The Breast. Elsevier BV; 2023; 10.1016/j.breast.2023.01.011
• Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction Cite
  KUBOTA Y, HAN Q, MASAKI N, HOZUMI C, HAMADA K, AOKI Y, et al. Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction. Anticancer Research. Anticancer Research USA Inc.; 2022; 42:5819-5823 10.21873/anticanres.16089
• Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study Cite
  Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, et al. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. Springer Science and Business Media LLC; 2022; 127:1799-1807 10.1038/s41416-022-01963-8
• Aspirin Use is Associated with Improvement in Distant Metastases Outcome in Patients with Residual Disease after Neoadjuvant Chemotherapy Cite
  Johns C, Cauble M, Liu Y, Rahimi A, Alluri P, Nwachukwu C, et al. Aspirin Use is Associated with Improvement in Distant Metastases Outcome in Patients with Residual Disease after Neoadjuvant Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2022; 114:e5 10.1016/j.ijrobp.2022.07.683
• Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer. Cite
  Barakat D, Mohamed R, Elnaggar M, Tarik D, Eid SM. Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:552-552 10.1200/jco.2022.40.16_suppl.552
• A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer Cite
  Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncology. Future Medicine Ltd; 2022; 10.2217/fon-2022-0310
• 248P Axillary nodal involvement (ANI) predictive model by primary histopathological features in invasive breast cancer (IBC): A real-world analysis of 1,400 cases Cite
  Cutuli B, Charles C. 248P Axillary nodal involvement (ANI) predictive model by primary histopathological features in invasive breast cancer (IBC): A real-world analysis of 1,400 cases. Annals of Oncology. Elsevier BV; 2022; 33:S236 10.1016/j.annonc.2022.03.270
• Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review Cite
  Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review. Cancers. MDPI AG; 2022; 14:1898 10.3390/cancers14081898
• Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer Cite
  Ye L, Rünger D, Angarita SA, Hadaya J, Baker JL, Lee MK, et al. Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06581-9
• Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches Cite
  Cescon DW, Kalinsky K, Parsons HA, Smith KL, Spears PA, Thomas A, et al. Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. Frontiers in Oncology. Frontiers Media SA; 2022; 11 10.3389/fonc.2021.667397
• Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics Cite
  Nelson DR, Brown J, Morikawa A, Method M. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLOS ONE. Public Library of Science (PLoS); 2022; 17:e0264637 10.1371/journal.pone.0264637
• Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer Cite
  Park KW, Kim SW, Han H, Park M, Han B, Ko EY, et al. Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-021-00364-z
• Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy? Cite
  Matar R, Barrio AV, Sevilimedu V, Le T, Heerdt A, Morrow M, et al. Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-021-11140-5
• Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making Cite
  Cocco D, ElSherif A, Wright MD, Dempster MS, Kruse ML, Li H, et al. Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 28:5723-5729 10.1245/s10434-021-10455-7
• The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis Cite
  Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, et al. The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 10.1093/jnci/djab202
• EPV008/#139 Role of KI67 in predicting survival in RH+/HER2- breast cancer according to axillary nodal involvement Cite
  Mejri N, Berrazega Y, Rachdi H, Harhira I, Boussen H. EPV008/#139 Role of KI67 in predicting survival in RH+/HER2- breast cancer according to axillary nodal involvement. E-Posters. BMJ Publishing Group Ltd; 2021; 10.1136/ijgc-2021-igcs.75
• A careful reassessment of anthracycline use in curable breast cancer Cite
  Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, et al. A careful reassessment of anthracycline use in curable breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00342-5
• Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging? Cite
  Schumacher K, Inciardi M, O’Neil M, Wagner JL, Shah I, Amin AL, et al. Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 185:567-572 10.1007/s10549-020-06047-w
• 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer Cite
  Dar H, Johansson A, Nordensköljd A, Iftimi A, Yau C, Perez-Tenorio G, et al. 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer. Annals of Oncology. Elsevier BV; 2021; 32:S23 10.1016/j.annonc.2021.03.020
• Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer Cite
  Adachi Y, Oze I, Sawaki M, Hattori M, Yoshimura A, Kotani H, et al. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer. Breast Cancer; 2021; 10.1007/s12282-021-01245-w
• Predictors of Nodal Pathological Complete Response in Asian Women with Stage II–III Node-Positive Breast Cancer Cite
  Montagna G, Tong Y, Ritter M, Levi J, Weber WP, Chen X, et al. Predictors of Nodal Pathological Complete Response in Asian Women with Stage II–III Node-Positive Breast Cancer. Oncology. S. Karger AG; 2021;:1-6 10.1159/000513454
• Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer Cite
  Jung EJ, Kim J, Kim J, Lee HS, Kwag S, Park J, et al. Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer. Medicine. Ovid Technologies (Wolters Kluwer Health); 2021; 100:e25000 10.1097/md.0000000000025000
• Delay in surgery is associated with axillary upstaging of clinically node negative breast cancer patients Cite
  Khader A, Chang S, Santamaria‐Barria J, Garland‐Kledzik M, Scholer A, Goldfarb M, et al. Delay in surgery is associated with axillary upstaging of clinically node negative breast cancer patients. Journal of Surgical Oncology. Wiley; 2020; 10.1002/jso.26332
• Low Levels of Omega-3 Long-Chain Polyunsaturated Fatty Acids Are Associated with Bone Metastasis Formation in Premenopausal Women with Breast Cancer: A Retrospective Study Cite
  Goupille C, Frank PG, Arbion F, Jourdan M, Guimaraes C, Pinault M, et al. Low Levels of Omega-3 Long-Chain Polyunsaturated Fatty Acids Are Associated with Bone Metastasis Formation in Premenopausal Women with Breast Cancer: A Retrospective Study. Nutrients. MDPI AG; 2020; 12:3832 10.3390/nu12123832
• Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial Cite
  Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, et al. Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial. Cancer. Wiley; 2020; 10.1002/cncr.33318
• Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Cite
  Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, et al. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:4603-4612 10.1245/s10434-020-08891-y
• Predicting the Survival of Triple-Negative Breast Cancer in Different Stages: A SEER Population Based Research Referring to Clinicopathological Factors Cite
  Chen S, Tang S, Li K, Wu J, Li X, Ren H, et al. Predicting the Survival of Triple-Negative Breast Cancer in Different Stages: A SEER Population Based Research Referring to Clinicopathological Factors. Cancer Investigation. Informa UK Limited; 2020; 38:549-558 10.1080/07357907.2020.1831010
• The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer Cite
  Grova MM, Strassle PD, Navajas EE, Gallagher KK, Ollila DW, Downs-Canner SM, et al. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 10.1245/s10434-020-09152-8
• Do Obese Patients Present With More Advanced Breast Cancer? Cite
  Wang M, Huang J, Chagpar AB. Do Obese Patients Present With More Advanced Breast Cancer?. The American Surgeon. SAGE Publications; 2020;:000313482094951 10.1177/0003134820949510
• Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer Cite
  Christgen M, Gluz O, Harbeck N, Kates RE, Raap M, Christgen H, et al. Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer. Cancer. Wiley; 2020; 126:4847-4858 10.1002/cncr.33104
• Breast cancer in women younger than 35 years old Cite
  Zouzoulas D, Tsolakidis D, Gitas G, Zafrakas M, Goulis DG, Douganiotis G, et al. Breast cancer in women younger than 35 years old. Archives of Gynecology and Obstetrics. Springer Science and Business Media LLC; 2020; 302:721-730 10.1007/s00404-020-05695-z
• Is it Wise to Omit Sentinel Node Biopsy in Elderly Patients with Breast Cancer? Cite
  Sun J, Mathias BJ, Sun W, Fulp WJ, Zhou J, Laronga C, et al. Is it Wise to Omit Sentinel Node Biopsy in Elderly Patients with Breast Cancer?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 28:320-329 10.1245/s10434-020-08759-1
• Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study Cite
  Gómez-Acebo I, Dierssen-Sotos T, Palazuelos-Calderón C, Pérez-Gómez B, Amiano P, Guevara M, et al. Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 181:667-678 10.1007/s10549-020-05600-x
• Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database Cite
  Fabiano V, Mandó P, Rizzo M, Ponce C, Coló F, Loza M, et al. Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database. JCO Global Oncology. American Society of Clinical Oncology (ASCO); 2020;:639-646 10.1200/jgo.19.00228
• Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy Cite
  Samiei S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, Simons JM, Kooreman LFS, et al. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2020; 271:574-580 10.1097/sla.0000000000003126
• De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study Cite
  Simons JM, Koppert LB, Luiten EJT, van der Pol CC, Samiei S, de Wilt JHW, et al. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:725-733 10.1007/s10549-020-05589-3
• Nodal positivity decreases with age in women with early‐stage, hormone receptor–positive breast cancer Cite
  Downs‐Canner SM, Gaber CE, Louie RJ, Strassle PD, Gallagher KK, Muss HB, et al. Nodal positivity decreases with age in women with early‐stage, hormone receptor–positive breast cancer. Cancer. Wiley; 2019; 126:1193-1201 10.1002/cncr.32668
• Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers Cite
  Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, et al. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 180:735-745 10.1007/s10549-020-05565-x
• Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence Cite
  Conforti F, Pala L, Pagan E, Viale G, Bagnardi V, Peruzzotti G, et al. Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research. Springer Science and Business Media LLC; 2019; 21 10.1186/s13058-019-1234-9
• Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy Cite
  Asaoka M, Narui K, Suganuma N, Chishima T, Yamada A, Sugae S, et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. European Journal of Surgical Oncology. Elsevier BV; 2019; 45:2289-2294 10.1016/j.ejso.2019.08.001
• Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma Cite
  Thornton MJ, Williamson HV, Westbrook KE, Greenup RA, Plichta JK, Rosenberger LH, et al. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3166-3177 10.1245/s10434-019-07564-9
• Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ Cite
  Hung P, Wang S, Killelea BK, Mougalian SS, Evans SB, Sedghi T, et al. Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ. JNCI Cancer Spectrum. Oxford University Press (OUP); 2019; 3 10.1093/jncics/pkz052
• Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials Cite
  Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 179:275-285 10.1007/s10549-019-05464-w
• Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers Cite
  Mamtani A, Zabor EC, Stempel M, Morrow M. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3269-3274 10.1245/s10434-019-07536-z
• Revisit the risk factors of recurrence in node involved HER2-positive breast cancer Cite
  Hasegawa Y, Kogawa T, Shimokawa M, Kusuhara S, Fujimoto Y, Harano K, et al. Revisit the risk factors of recurrence in node involved HER2-positive breast cancer. Annals of Oncology. Elsevier BV; 2019; 30:vi114 10.1093/annonc/mdz338.102
• Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials Cite
  Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer J, Seiler S, et al. Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials. Annals of Oncology. Elsevier BV; 2019; 30:v62-v63 10.1093/annonc/mdz240.014
• The impact of chemotherapy sequence on survival in node‐positive invasive lobular carcinoma Cite
  Tamirisa N, Williamson HV, Thomas SM, Westbrook KE, Greenup RA, Plichta JK, et al. The impact of chemotherapy sequence on survival in node‐positive invasive lobular carcinoma. Journal of Surgical Oncology. Wiley; 2019; 10.1002/jso.25492
• The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer Cite
  Poodt IG, Schipper R, Vugts G, Woensdregt K, van der Sangen M, Voogd AC, et al. The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer. European Journal of Surgical Oncology. Elsevier BV; 2018; 44:1714-1719 10.1016/j.ejso.2018.07.005
• Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response Cite
  Kozak MM, Jacobson CE, von Eyben R, Pollom EL, Telli M, Horst KC. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2018; 16:845-850 10.6004/jnccn.2018.7022
• Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival Cite
  Tamirisa N, Thomas SM, Fayanju OM, Greenup RA, Rosenberger LH, Hyslop T, et al. Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2018; 25:2890-2898 10.1245/s10434-018-6595-2
• The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer Cite
  Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 170:647-656 10.1007/s10549-018-4796-9
• Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast Cite
  Morrow E, Lannigan A, Doughty J, Litherland J, Mansell J, Stallard S, et al. Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. British Journal of Surgery. Wiley; 2018; 105:987-995 10.1002/bjs.10791
• Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study Cite
  Mutschler NS, Scholz C, Friedl TW, Zwingers T, Fasching PA, Beckmann MW, et al. Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. Clinical Breast Cancer. Elsevier BV; 2018; 18:175-183 10.1016/j.clbc.2018.01.008
• Treatment Outcomes in Male Breast Cancer: A Retrospective Analysis of 161 Patients Cite
  Wan B, Ganesh V, Zhang L, Sousa P, Drost L, Lorentz J, et al. Treatment Outcomes in Male Breast Cancer: A Retrospective Analysis of 161 Patients. Clinical Oncology. Elsevier BV; 2018; 30:354-365 10.1016/j.clon.2018.02.026
• Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort Cite
  Lafourcade A, His M, Baglietto L, Boutron-Ruault M, Dossus L, Rondeau V. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4076-4
• Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Cite
  Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:561-564 10.1200/jco.2016.71.0947
• Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience Cite
  Houzé de l’Aulnoit A, Rogoz B, Pinçon C, Houzé de l’Aulnoit D. Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience. The Breast. Elsevier BV; 2018; 37:80-88 10.1016/j.breast.2017.10.008
• 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years Cite
  Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine. Massachusetts Medical Society; 2017; 377:1836-1846 10.1056/nejmoa1701830
• Young Women Who Achieve Pathologic Complete Response in the Axillary Lymph Nodes Do Not Have Improved Survival Compared to Those Who Remain Lymph Node Positive after Neoadjuvant Chemotherapy Cite
  Kozak M, Jacobson C, Horst K. Young Women Who Achieve Pathologic Complete Response in the Axillary Lymph Nodes Do Not Have Improved Survival Compared to Those Who Remain Lymph Node Positive after Neoadjuvant Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2017; 99:E26 10.1016/j.ijrobp.2017.06.653
• Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis Cite
  Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA. American Medical Association (AMA); 2017; 318:918 10.1001/jama.2017.11470
• Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy Cite
  Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, et al. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2556-2562 10.1245/s10434-017-5898-z
• Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors Cite
  Parise CA, Caggiano V. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:743-750 10.1007/s10549-017-4383-5
• Patterns and predictors of first and subsequent recurrence in women with early breast cancer Cite
  Geurts YM, Witteveen A, Bretveld R, Poortmans PM, Sonke GS, Strobbe LJA, et al. Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 165:709-720 10.1007/s10549-017-4340-3
• Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy Cite
  Nogi H, Uchida K, Mimoto R, Kamio M, Shioya H, Toriumi Y, et al. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy. Clinical Breast Cancer. Elsevier BV; 2017; 17:644-649 10.1016/j.clbc.2017.05.002
• Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study Cite
  Buono G, Giuliano M, De Angelis C, Lauria R, Forestieri V, Pensabene M, et al. Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. Clinical Breast Cancer. Elsevier BV; 2017; 17:559-563 10.1016/j.clbc.2017.05.007
• Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study Cite
  Buono G, Giuliano M, De Angelis C, Lauria R, Forestieri V, Pensabene M, et al. Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. Clinical Breast Cancer. Elsevier BV; 2017; 17:559-563 10.1016/j.clbc.2017.05.007
• Lymph node status as a prognostic factor in BRCA-positive breast cancer Cite
  Lee J, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, et al. Lymph node status as a prognostic factor in BRCA-positive breast cancer. Journal of Surgical Research. Elsevier BV; 2017; 215:125-131 10.1016/j.jss.2017.03.065
• Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy? Cite
  Stüber T, Novopashenny I, Diessner J, Bartmann C, Stein R, Krockenberger M, et al. Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?. Oncology. S. Karger AG; 2017; 92:317-324 10.1159/000455050
• Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era Cite
  Miyashita M, Tada H, Suzuki A, Watanabe G, Hirakawa H, Amari M, et al. Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era. Surgical Oncology. Elsevier BV; 2017; 26:163-170 10.1016/j.suronc.2017.03.003
• Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis Cite
  Abrams MJ, Koffer PP, Wazer DE, Hepel JT. Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2017; 98:384-391 10.1016/j.ijrobp.2017.02.007
• Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study Cite
  de Boniface J, Frisell J, Bergkvist L, Andersson Y. Ten-year report on axillary recurrence after negative sentinel node biopsy for breast cancer from the Swedish Multicentre Cohort Study. British Journal of Surgery. Oxford University Press (OUP); 2017; 104:238-247 10.1002/bjs.10411
• Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: A systematic review and meta-analysis Cite
  Liang S, Hallet J, Simpson JS, Tricco AC, Scheer AS. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: A systematic review and meta-analysis. Journal of Geriatric Oncology. Elsevier BV; 2017; 8:140-147 10.1016/j.jgo.2016.12.003
• Factors Associated With Disease Recurrence in Breast Cancer Patients With Negative Sentinel Lymph Node Biopsy Cite
  Navarro-Rodríguez E, Díaz-Jiménez N, Ruiz-Rabelo J, Gómez-Luque I, Bascuñana-Estudillo G, Rioja-Torres P, et al. Factors Associated With Disease Recurrence in Breast Cancer Patients With Negative Sentinel Lymph Node Biopsy. Clinical Breast Cancer. Elsevier BV; 2016; 16:e181-e186 10.1016/j.clbc.2016.06.013
• Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy Cite
  Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Bellon JR, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 161:173-179 10.1007/s10549-016-4031-5
• Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients Cite
  El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. The American Journal of Surgery. Elsevier BV; 2016; 212:969-981 10.1016/j.amjsurg.2016.07.018
• Axillary lymph node micrometastases decrease triple-negative early breast cancer survival Cite
  Houvenaeghel G, Sabatier R, Reyal F, Classe JM, Giard S, Charitansky H, et al. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 115:1024-1031 10.1038/bjc.2016.283
• The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance Cite
  Youssef MM, Cameron D, Pucher PH, Olsen S, Ferguson D. The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance. The Breast. Elsevier BV; 2016; 30:101-104 10.1016/j.breast.2016.09.005
• Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients Cite
  El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. The American Journal of Surgery. Elsevier BV; 2016; 212:969-981 10.1016/j.amjsurg.2016.07.018
• Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger Cite
  Plichta JK, Rai U, Tang R, Coopey SB, Buckley JM, Gadd MA, et al. Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2016; 23:3212-3220 10.1245/s10434-016-5404-z
• Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer Cite
  Lee E, Han W, Kim MK, Kim J, Yoo T, Lee MH, et al. Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2423-x
• Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients Cite
  Laurberg T, Lyngholm CD, Christiansen P, Alsner J, Overgaard J. Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients. Radiotherapy and Oncology. Elsevier BV; 2016; 120:98-106 10.1016/j.radonc.2016.05.006
• Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database Cite
  Wang X, Jiang Y, Li J, Song C, Shao Z. Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database. Oncotarget. Impact Journals, LLC; 2016; 7:46636-46645 10.18632/oncotarget.9432
• Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cite
  Bradley MC, Black A, Freedman AN, Barron TI. Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. Wiley; 2016; 122:2067-2075 10.1002/cncr.30004
• Long term results of treatment of breast cancer without axillary surgery – Predicting a SOUND approach? Cite
  O'Connell R, Rusby J, Stamp G, Conway A, Roche N, Barry P, et al. Long term results of treatment of breast cancer without axillary surgery – Predicting a SOUND approach?. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:942-948 10.1016/j.ejso.2016.03.027
• Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer Cite
  Morrow M. Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2016; 2:516 10.1001/jamaoncol.2015.4919
• Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands Cite
  Vugts G, Maaskant-Braat A, de Roos W, Voogd A, Nieuwenhuijzen G. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:956-964 10.1016/j.ejso.2016.03.023
• Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population Cite
  Lim ST, Choi JE, Kim SJ, Kim HA, Kim JY, Park HK, et al. Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 156:473-483 10.1007/s10549-016-3771-6
• Axillary reverse mapping in patients with breast cancer: Is it oncologically safe? Cite
  Ngui NK, French J, Kilby CJ, Pathmanathan N, Elder EE. Axillary reverse mapping in patients with breast cancer: Is it oncologically safe?. Journal of Surgical Oncology. Wiley; 2016; 113:726-731 10.1002/jso.24231
• Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer Cite
  Truin W, Roumen RM, Siesling S, van der Heiden-van der Loo M, Lobbezoo DJ, Tjan-Heijnen VC, et al. Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2016; 16:e75-e82 10.1016/j.clbc.2016.03.007
• The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy? Cite
  Sun Y, Liu X, Cui S, Li L, Tian P, Liu S, et al. The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?. Tumor Biology. Springer Science and Business Media LLC; 2016; 37:9555-9563 10.1007/s13277-016-4844-1
• Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy Cite
  Xin F, Yu Y, Yang Z, Hou L, Mao J, Xia L, et al. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy. Tumor Biology. Springer Science and Business Media LLC; 2016; 37:8445-8454 10.1007/s13277-015-4640-3
• Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy Cite
  Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Medicine. Springer Science and Business Media LLC; 2015; 13 10.1186/s12916-015-0540-z
• Tumor Invasiveness, Not Lymphangiogenesis, Is Correlated with Lymph Node Metastasis and Unfavorable Prognosis in Young Breast Cancer Patients (≤35 Years) Cite
  Zhang Z, Han Y, Nian Q, Chen G, Cui S, Wang X. Tumor Invasiveness, Not Lymphangiogenesis, Is Correlated with Lymph Node Metastasis and Unfavorable Prognosis in Young Breast Cancer Patients (≤35 Years). PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0144376 10.1371/journal.pone.0144376
• Association between Lymph Node Ratio and Disease Specific Survival in Breast Cancer Patients with One or Two Positive Lymph Nodes Stratified by Different Local Treatment Modalities Cite
  Hong R, Dai Z, Zhu W, Xu B. Association between Lymph Node Ratio and Disease Specific Survival in Breast Cancer Patients with One or Two Positive Lymph Nodes Stratified by Different Local Treatment Modalities. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0138908 10.1371/journal.pone.0138908
• Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer Cite
  Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, et al. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2015; 23:830-843 10.1007/s12282-015-0649-0
• Breast cancer prognosis and isolated tumor cell findings in axillary lymph nodes after core needle biopsy and fine needle aspiration cytology Cite
  Liikanen J, Leidenius M, Joensuu H, Vironen J, Heikkilä P, Meretoja T. Breast cancer prognosis and isolated tumor cell findings in axillary lymph nodes after core needle biopsy and fine needle aspiration cytology. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2016; 42:64-70 10.1016/j.ejso.2015.08.170
• Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients Cite
  Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MMA. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. BMJ. BMJ; 2015;:h4901 10.1136/bmj.h4901
• Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases Cite
  Jeong H, Jones D, Liao S, Wattson DA, Cui CH, Duda DG, et al. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107 10.1093/jnci/djv155
• Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer Cite
  Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L, et al. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. European Journal of Cancer. Elsevier BV; 2015; 51:1874-1881 10.1016/j.ejca.2015.07.003
• Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry Cite
  Mattes MD, Bhatia JK, Metzger D, Ashamalla H, Katsoulakis E. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry. Journal of Breast Cancer. Korean Breast Cancer Society; 2015; 18:143 10.4048/jbc.2015.18.2.143
• Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance) Cite
  Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, et al. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107 10.1093/jnci/djv179
• Occult metastases in node-negative breast cancer: A Surveillance, Epidemiology, and End Results−based analysis Cite
  Kimbrough CW, McMasters KM, Quillo A, Ajkay N. Occult metastases in node-negative breast cancer: A Surveillance, Epidemiology, and End Results−based analysis. Surgery. Elsevier BV; 2015; 158:494-500 10.1016/j.surg.2015.03.049
• Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma Cite
  Chu Z, Lin H, Liang X, Huang R, Tang J, Bao Y, et al. Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2015; 45:637-641 10.1093/jjco/hyv052
• Postmastectomy radiation therapy in T3 node-negative breast cancer Cite
  Elmore L, Deshpande A, Daly M, Margenthaler JA. Postmastectomy radiation therapy in T3 node-negative breast cancer. Journal of Surgical Research. Elsevier BV; 2015; 199:90-96 10.1016/j.jss.2015.04.012
• No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study Cite
  Nordenskjöld A, Fohlin H, Albertsson P, Arnesson L, Chamalidou C, Einbeigi Z, et al. No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. Annals of Oncology. Elsevier BV; 2015; 26:1149-1154 10.1093/annonc/mdv159
• Operable Breast Cancer of the Inner Hemisphere Is Associated with Poor Survival Cite
  Xue C, Peng RJ, Wang SS, Shi YX, An X, Xu F, et al. Operable Breast Cancer of the Inner Hemisphere Is Associated with Poor Survival. Journal of Breast Cancer. Korean Breast Cancer Society; 2015; 18:36 10.4048/jbc.2015.18.1.36
• Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes Cite
  He Z, Wu S, Zhou J, Li F, Lin Q, Lin H, et al. Postmastectomy Radiotherapy Improves Disease-Free Survival of High Risk of Locoregional Recurrence Breast Cancer Patients with T1-2 and 1 to 3 Positive Nodes. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0119105 10.1371/journal.pone.0119105
• Effect of Implant vs. Tissue Reconstruction on Cancer Specific Survival Varies by Axillary Lymph Node Status in Breast Cancer Patients Cite
  Ouyang Q, Zhu L, Chen K, Su F. Effect of Implant vs. Tissue Reconstruction on Cancer Specific Survival Varies by Axillary Lymph Node Status in Breast Cancer Patients. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0118161 10.1371/journal.pone.0118161
• Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment? Cite
  Tognela A, Beith J, Kiely B, Bastick P, Lynch J, Descallar J, et al. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?. Clinical Breast Cancer. Elsevier BV; 2015; 15:277-284 10.1016/j.clbc.2014.12.012
• Postmastectomy Radiation for N2/N3 Breast Cancer: Factors Associated with Low Compliance Rate Cite
  Chu QD, Caldito G, Miller JK, Townsend B. Postmastectomy Radiation for N2/N3 Breast Cancer: Factors Associated with Low Compliance Rate. Journal of the American College of Surgeons. Elsevier BV; 2015; 220:659-669 10.1016/j.jamcollsurg.2014.12.045
• Deviation from the Standard of Care for Early Breast Cancer in the Elderly: What are the Consequences? Cite
  Sun SX, Hollenbeak CS, Leung AM. Deviation from the Standard of Care for Early Breast Cancer in the Elderly: What are the Consequences?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2014; 22:2492-2499 10.1245/s10434-014-4290-5
• The prognostic value of lymph node status among breast cancer subtypes Cite
  Liao G, Chou Y, Hsu H, Dai M, Yu J. The prognostic value of lymph node status among breast cancer subtypes. The American Journal of Surgery. Elsevier BV; 2015; 209:717-724 10.1016/j.amjsurg.2014.05.029
• Impact of sentinel node tumor burden on outcome of invasive breast cancer patients Cite
  Meattini I, Desideri I, Saieva C, Francolini G, Scotti V, Bonomo P, et al. Impact of sentinel node tumor burden on outcome of invasive breast cancer patients. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:1195-1202 10.1016/j.ejso.2014.08.471
• Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-Year results of trial and out-trial patients Cite
  Martelli G, Boracchi P, Orenti A, Lozza L, Maugeri I, Vetrella G, et al. Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-Year results of trial and out-trial patients. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:805-812 10.1016/j.ejso.2014.03.029
• Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment Cite
  McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, et al. Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2014; 89:392-398 10.1016/j.ijrobp.2014.02.013
• The sensitivity of pre-operative axillary staging in breast cancer: Comparison of invasive lobular and ductal carcinoma Cite
  Topps A, Clay V, Absar M, Howe M, Lim Y, Johnson R, et al. The sensitivity of pre-operative axillary staging in breast cancer: Comparison of invasive lobular and ductal carcinoma. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2014; 40:813-817 10.1016/j.ejso.2014.03.026
• Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials Cite
  EBCTCG (Early Breast Cancer Trialists' Collaborative Group) . Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. The Lancet. Elsevier BV; 2014; 383:2127-2135 10.1016/s0140-6736(14)60488-8
• Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database Cite
  Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, et al. Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e89778 10.1371/journal.pone.0089778
• Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor Cite
  Narbe U, Bendahl P, Grabau D, Rydén L, Ingvar C, Fernö M. Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. SpringerPlus. Springer Science and Business Media LLC; 2014; 3 10.1186/2193-1801-3-70
• Post-Mastectomy Radiotherapy for Breast Cancer Patients with T1-T2 and 1-3 Positive Lymph Nodes: a Meta-Analysis Cite
  Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-Mastectomy Radiotherapy for Breast Cancer Patients with T1-T2 and 1-3 Positive Lymph Nodes: a Meta-Analysis. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e81765 10.1371/journal.pone.0081765
• Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 Cite
  Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE, et al. Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:3960-3966 10.1200/jco.2011.40.8369
• HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics Cite
  Ataseven B, Gologan D, Gunesch A, Kehl V, Hoegel B, Beer M, et al. HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics. Breast Care. S. Karger AG; 2012; 7:465-470 10.1159/000345467
• Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients Cite
  Pogoda K, Niwińska A, Murawska M, Pieńkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Medical Oncology. Springer Science and Business Media LLC; 2013; 30 10.1007/s12032-012-0388-4
• Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy Cite
  Ju NR, Jeffe DB, Keune J, Aft R. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 137:195-201 10.1007/s10549-012-2312-1
• Prediction of axillary lymph node status in male breast carcinoma Cite
  Vaysse C, Sroussi J, Mallon P, Feron J, Rivain A, Ngo C, et al. Prediction of axillary lymph node status in male breast carcinoma. Annals of Oncology. Elsevier BV; 2013; 24:370-376 10.1093/annonc/mds283
• Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000 Cite
  Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete Axillary Lymph Node Dissection Versus Clinical Follow-up in Breast Cancer Patients with Sentinel Node Micrometastasis: Final Results from the Multicenter Clinical Trial AATRM 048/13/2000. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 20:120-127 10.1245/s10434-012-2569-y
• Tumor Stage Affects Risk and Prognosis of Contralateral Breast Cancer: Results From a Large Swedish-Population–Based Study Cite
  Vichapat V, Garmo H, Holmqvist M, Liljegren G, Wärnberg F, Lambe M, et al. Tumor Stage Affects Risk and Prognosis of Contralateral Breast Cancer: Results From a Large Swedish-Population–Based Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:3478-3485 10.1200/jco.2011.39.3645
• Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection Cite
  Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, et al. Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2012; 256:428-436 10.1097/sla.0b013e3182654494
• The Impact of the Size of Nodal Metastases on Recurrence Risk in Breast Cancer Patients With 1-3 Positive Axillary Nodes After Mastectomy Cite
  Harris EE, Freilich J, Lin H, Chuong M, Acs G. The Impact of the Size of Nodal Metastases on Recurrence Risk in Breast Cancer Patients With 1-3 Positive Axillary Nodes After Mastectomy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2013; 85:609-614 10.1016/j.ijrobp.2012.05.050
• Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer Cite
  Kim J, Han W, Moon H, Ahn SK, Shin H, You J, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Research. Springer Science and Business Media LLC; 2012; 14 10.1186/bcr3221
• Multifocality and multicentricity in breast cancer and survival outcomes Cite
  Lynch S, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz T, et al. Multifocality and multicentricity in breast cancer and survival outcomes. Annals of Oncology. Elsevier BV; 2012; 23:3063-3069 10.1093/annonc/mds136
• Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report Cite
  Karlsson P, Cole B, Chua B, Price K, Lindtner J, Collins J, et al. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Annals of Oncology. Elsevier BV; 2012; 23:2852-2858 10.1093/annonc/mds118
• Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort Cite
  Markkula A, Bromée A, Henningson M, Hietala M, Ringberg A, Ingvar C, et al. Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2012; 23:1307-1316 10.1007/s10552-012-0008-9
• Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series. Cite
  Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, et al. Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:e21102-e21102 10.1200/jco.2012.30.15_suppl.e21102
• Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency Cite
  Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. Oxford University Press (OUP); 2012; 33:1319-1326 10.1093/carcin/bgs187
• Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy? Cite
  Hamamoto Y, Ohsumi S, Aogi K, Shinohara S, Nakajima N, Kataoka M, et al. Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?. Breast Cancer. Springer Science and Business Media LLC; 2012; 21:177-182 10.1007/s12282-012-0369-7
• Prognostic Value of Molecular Subtypes, Ki67 Expression and Impact of Postmastectomy Radiation Therapy in Breast Cancer Patients With Negative Lymph Nodes After Mastectomy Cite
  Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R. Prognostic Value of Molecular Subtypes, Ki67 Expression and Impact of Postmastectomy Radiation Therapy in Breast Cancer Patients With Negative Lymph Nodes After Mastectomy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2012; 84:1123-1132 10.1016/j.ijrobp.2012.02.047
• Tumour characteristics among women with very low-risk breast cancer Cite
  Narod SA, Valentini A, Nofech-Mozes S, Sun P, Hanna W. Tumour characteristics among women with very low-risk breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 134:1241-1246 10.1007/s10549-012-2065-x
• Invasive lobular breast cancer: subtypes and outcome Cite
  Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 133:713-723 10.1007/s10549-012-2002-z
• Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China Cite
  Zhang L, Hao C, Dong G, Tong Z. Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China. Breast Care. S. Karger AG; 2012; 7:13-17 10.1159/000336539
• Should Postmastectomy Radiotherapy to the Chest Wall and Regional Lymph Nodes Be Standard for Patients with 1–3 Positive Lymph Nodes? Cite
  Offersen BV, Brodersen H, Nielsen MM, Overgaard J, Overgaard M. Should Postmastectomy Radiotherapy to the Chest Wall and Regional Lymph Nodes Be Standard for Patients with 1–3 Positive Lymph Nodes?. Breast Care. S. Karger AG; 2011; 6:347-351 10.1159/000333250
• Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique? Cite
  Wasif N, McCullough AE, Gray RJ, Pockaj BA. Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique?. Journal of Surgical Oncology. Wiley; 2011; 105:586-590 10.1002/jso.22132
• Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials Cite
  . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. The Lancet. Elsevier BV; 2011; 378:1707-1716 10.1016/s0140-6736(11)61629-2
• Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation Cite
  Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, et al. Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 18:3164-3173 10.1245/s10434-011-1920-z
• Prevalence of lymphoedema more than five years after breast cancer treatment Cite
  Lopez Penha T, Slangen J, Heuts E, Voogd A, Von Meyenfeldt M. Prevalence of lymphoedema more than five years after breast cancer treatment. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:1059-1063 10.1016/j.ejso.2011.09.001
• Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location Cite
  Vestjens JH, de Boer M, van Diest PJ, van Deurzen CH, van Dijck JA, Borm GF, et al. Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:645-651 10.1007/s10549-011-1771-0
• Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period Cite
  Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, et al. Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 19:1107-1114 10.1245/s10434-011-1907-9
• Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer Cite
  Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, et al. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. Wiley; 2011; 118:1507-1514 10.1002/cncr.26458
• Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breast cancer Cite
  Tvedskov TF, Jensen M, Kroman N, Balslev E. Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:223-229 10.1007/s10549-011-1720-y
• Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast Cite
  Fernandez B, Paish EC, Green AR, Lee AHS, Macmillan RD, Ellis IO, et al. Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. Journal of Clinical Pathology. BMJ; 2011; 64:995-1000 10.1136/jclinpath-2011-200151
• Beta Blockers and Breast Cancer Mortality: A Population- Based Study Cite
  Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta Blockers and Breast Cancer Mortality: A Population- Based Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:2635-2644 10.1200/jco.2010.33.5422
• Biologic markers determine both the risk and the timing of recurrence in breast cancer Cite
  Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, et al. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:607-616 10.1007/s10549-011-1564-5
• Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes Cite
  Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 127:713-720 10.1007/s10549-011-1465-7
• Long-term observational follow-up study of breast cancer diagnosed in women ≤40 years old Cite
  Karihtala P, Winqvist R, Bloigu R, Jukkola-Vuorinen A. Long-term observational follow-up study of breast cancer diagnosed in women ≤40 years old. The Breast. Elsevier BV; 2010; 19:456-461 10.1016/j.breast.2010.05.001
• Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller Cite
  Lai H, Kuo S, Chen L, Chi C, Chen S, Chang T, et al. Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:18-24 10.1016/j.ejso.2010.10.003
• Prognosis and Outcome of Small (≤1 cm), Node‐Negative Breast Cancer on the Basis of Hormonal and HER‐2 Status Cite
  Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, et al. Prognosis and Outcome of Small (≤1 cm), Node‐Negative Breast Cancer on the Basis of Hormonal and HER‐2 Status. The Oncologist. Wiley; 2010; 15:1043-1049 10.1634/theoncologist.2010-0036
• Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study Cite
  Maaskant-Braat AJ, van de Poll-Franse LV, Voogd AC, Coebergh JWW, Roumen RM, Nolthenius-Puylaert MCT, et al. Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 127:195-203 10.1007/s10549-010-1086-6
• The impact of young age on breast cancer outcome Cite
  Livi L, Meattini I, Saieva C, Borghesi S, Scotti V, Petrucci A, et al. The impact of young age on breast cancer outcome. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2010; 36:639-645 10.1016/j.ejso.2010.05.016
• Significance of E-cadherin expression in triple-negative breast cancer Cite
  Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, et al. Significance of E-cadherin expression in triple-negative breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 103:249-255 10.1038/sj.bjc.6605735
• Prognosis and pathology of screen-detected carcinomas Cite
  Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, et al. Prognosis and pathology of screen-detected carcinomas. Cancer. Wiley; 2010; 117:1360-1368 10.1002/cncr.25613
• Determination of clear margin in breast-conserving surgery: Is 1 mm needed? Cite
  Geffrelot J, Toudic Emily F, Levy C, Blanc Fournier C, Segura C, Switsers O, et al. Determination of clear margin in breast-conserving surgery: Is 1 mm needed?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:515-515 10.1200/jco.2010.28.15_suppl.515
• Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials. Cite
  Huober JB, Gelber S, Thürlimann B, Regan MM, Price KN, Goldhirsch A, et al. Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:630-630 10.1200/jco.2010.28.15_suppl.630
• The metastatic capacity of multifocal breast carcinomas: extensive tumors versus tumors of limited extent Cite
  Tot T. The metastatic capacity of multifocal breast carcinomas: extensive tumors versus tumors of limited extent. Human Pathology. Elsevier BV; 2009; 40:199-205 10.1016/j.humpath.2008.07.001
• Improved Staging in Node-Positive Breast Cancer Patients Using Lymph Node Ratio: Results in 1,788 Patients with Long-term Follow-Up Cite
  Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA. Improved Staging in Node-Positive Breast Cancer Patients Using Lymph Node Ratio: Results in 1,788 Patients with Long-term Follow-Up. Journal of the American College of Surgeons. Elsevier BV; 2010; 210:797-805.e1 10.1016/j.jamcollsurg.2010.02.045
• Prognostic Significance of Number of Positive Nodes: A Long-Term Study of One to Two Nodes Versus Three Nodes in Breast Cancer Patients Cite
  Tai P, Yu E, Joseph K. Prognostic Significance of Number of Positive Nodes: A Long-Term Study of One to Two Nodes Versus Three Nodes in Breast Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2010; 77:180-187 10.1016/j.ijrobp.2009.04.073
• Subsets of Women with Close or Positive Margins after Breast Conserving Surgery with High Local Recurrence Risk Despite Breast Plus Boost Radiotherapy Cite
  Truong P, Lupe K, Alexander C, Lesperance M, Tyldesley S. Subsets of Women with Close or Positive Margins after Breast Conserving Surgery with High Local Recurrence Risk Despite Breast Plus Boost Radiotherapy. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2010; 78:S52-S53 10.1016/j.ijrobp.2010.07.157
• The prognostic impact of occult nodal metastasis in early breast carcinoma Cite
  Park D, Kåresen R, Naume B, Synnestvedt M, Beraki E, Sauer T. The prognostic impact of occult nodal metastasis in early breast carcinoma. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 118:57-66 10.1007/s10549-009-0340-2
• Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Cite
  Aitken S, Thomas J, Langdon S, Harrison D, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Annals of Oncology. Elsevier BV; 2010; 21:1254-1261 10.1093/annonc/mdp427
• Presenting Features of Breast Cancer Differ by Molecular Subtype Cite
  Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, et al. Presenting Features of Breast Cancer Differ by Molecular Subtype. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2009; 16:2705-2710 10.1245/s10434-009-0606-2
• Time-varying pattern of recurrence risk for Chinese breast cancer patients Cite
  Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, et al. Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 114:527-535 10.1007/s10549-008-0022-5
• Axillary Sentinel Lymph Nodes Can Be Falsely Positive Due to Iatrogenic Displacement and Transport of Benign Epithelial Cells in Patients With Breast Carcinoma Cite
  Bleiweiss IJ, Nagi CS, Jaffer S. Axillary Sentinel Lymph Nodes Can Be Falsely Positive Due to Iatrogenic Displacement and Transport of Benign Epithelial Cells in Patients With Breast Carcinoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2006; 24:2013-2018 10.1200/jco.2005.04.7076
• The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium Cite
  Ip MM, McGee SO, Masso-Welch PA, Ip C, Meng X, Ou L, et al. The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium. Carcinogenesis. Oxford University Press (OUP); 2007; 28:1269-1276 10.1093/carcin/bgm018